Gastric cancer (advanced) capecitabine: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Capectabine for the treatment of advanced gastric cancer and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 11 June 2010.
Gastric cancer (advanced) capecitabine: final appraisal determination
Gastric cancer (advanced) capecitabine: pre meeting briefing
Gastric cancer (advanced) capecitabine: evidence review group report
Gastric cancer (advanced) capecitabine: non-manufacturer submissions
Gastric cancer (advanced) capecitabine: manufacturer submission - Roche
Gastric cancer (advanced) capecitabine: clarification letters
Gastric cancer (advanced) capecitabine: expert written personal statements
This page was last updated: 25 May 2010